Prescient Therapeutics Ltd

ASX:PTX ISIN:AU000000PTX3

Prescient Therapeutics Limited is a clinical-stage oncology company. The Company's principal activities include in-licensing of intellectual property; the preparation for and conduct of clinical trials relating to the Company's products; business development associated with the promotion of its technologies and products, and business development associated with developing collaborative, partnership relationships and corporate transactions. 
 
           

Voir en d'autres langues

Nouvelles

###

137,644 COMPANY PROFILE VIEWS

  • This Page Viewed: (7 derniers jours: 20) (Last 30 Days: 82) (Since Published: 10534) 

Company Data

    Fax
  • (03) 9853 5134 
  • Principal Sector
  • Health & Pharm 
  • Principal Industry
  • Biotechnology 
  • Homepage
  • www.virax.com.au/

More News Results

  • 2025/03/31: Prescient Therapeutics - Investor Briefing*
  • 2025/03/26: PTX Opens First Clinical site for PTX-100 Phase 2a Study*
  • 2025/03/24: Change of Chief Medical Officer*
  • 2025/03/21: PTX-100 clinical data presented at leading TCL meeting*
  • 2025/03/17: Change of Director's Interest Notice*
  • 2025/03/11: Change of Board Chair*
  • 2025/02/21: Appendix 4D and Half Year Financial Report*
  • 2025/01/31: December 2024 Quarterly Update and Appendix 4C - amended*
  • 2025/01/31: December 2024 Quarterly Update and Appendix 4C*
  • 2025/01/23: OmniCAR technical issues resolved and program to progress*
*refer to company website